Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome

12 de novembro de 2026 atualizado por: My Myracle Sdn.Bhd

Effects of PosBion® Supplementation on Barrier-Related Biomarkers in Adults With Irritable Bowel Syndrome

Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.

This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).

The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.

Visão geral do estudo

Descrição detalhada

Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.

PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.

Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.

The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.

The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.

Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.

Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.

The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.

Tipo de estudo

Intervencional

Inscrição (Estimado)

55

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults aged 18 years or older
  • Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
  • Willing to comply with interventional plan
  • Willing to give consent

Exclusion Criteria:

  • History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
  • Current use of gastrointestinal health supplements
  • Current use of antibiotics or antiviral medications
  • Current use of probiotic, prebiotic, or postbiotic supplements
  • Major surgery within the previous 6 months.
  • Pregnant or lactating woman

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PosBion® Supplementation

Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.

PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.

Outros nomes:
  • PosBion®

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Salivary Interleukin-8 (IL-8) Concentration
Prazo: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12

Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.

Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
Change in Salivary Myeloperoxidase (MPO)
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lactoferrin
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Secretory Immunoglobulin A (sIgA)
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgE
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgM
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgG
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Baseline, Week 4, Week 8, and Week 12
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Serotonin
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.

Baseline, Week 4, Week 8, and Week 12

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in Salivary Zonulin
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lipopolysaccharide (LPS)
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary LPS-Binding Protein (LBP)
Prazo: Baseline, Week 4, Week 8, and Week 12

Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.

Baseline, Week 4, Week 8, and Week 12

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de novembro de 2026

Conclusão Primária (Estimado)

15 de fevereiro de 2027

Conclusão do estudo (Estimado)

15 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.

Prazo de Compartilhamento de IPD

Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.

Critérios de acesso de compartilhamento IPD

Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever